Clinical Trial Update: Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection [Phase 2]

View source ↗

Summary

A Phase 2 trial update assesses the efficacy, safety, tolerability and pharmacokinetics of KAE609 in adults with acute, uncomplicated malaria caused by Plasmodi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• KAE609 (cipargamin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Malaria | Phase 2 | Status: COMPLETED